Sanofi/Alnylam’s haemophilia drug hits another safety speed-bump

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating hemophilia has hit a setback after the company voluntarily placed its late-stage trials of fitusiran on hold because of safety issues.